Dyspareunia future or investigational therapies

Dyspareunia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dyspareunia from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dyspareunia future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dyspareunia future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dyspareunia future or investigational therapies
CDC on Dyspareunia future or investigational therapies
Dyspareunia future or investigational therapies in the news
Blogs on Dyspareunia future or investigational therapies
Directions to Hospitals Treating Dyspareunia
Risk calculators and risk factors for Dyspareunia future or investigational therapies

Overview

More research must be done to suggest a strong genetic link with Genito-Pelvic Pain/Penetration Disorder (GPPPD).

Future or investigational therapies

potential genetic predisposition to chronic inflammation among vestibulodynia afflicted women. This genetic polymorphism leads to a reduced capacity to terminate and to an exaggerated inflammatory response. More research must be done to suggest a strong genetic link with Genito-Pelvic Pain/Penetration Disorder (GPPPD).